Evidence mapPaperPMID 40464563Full record

ReviewJournal of virology2025

Applications and limitations of the passenger hypothesis for HIV reservoir persistence and cure.

Joshua T Schiffer, Joseph C Mudd, Annukka A R Antar, Adam M Spivak, Daniel B Reeves

Abstract readReview
In one paragraph

Review in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Tenofovir, Interferon Pathways, and Mucosal Immunity: Implications for People Living With HIV.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Joshua T SchifferVaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID 0000-0002-2598-1621
Joseph C MuddTulane University National Primate Center, Covington, Louisiana, USA.
Annukka A R AntarDepartment of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Adam M SpivakDepartment of Medicine, University of Utah, Salt Lake City, Utah, USA.
Daniel B ReevesVaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID 0000-0001-5684-9538

Funding

Tulane National Primate Research CenterP51OD011104 · TULANE UNIVERSITY OF LOUISIANA · 2025 to 2025
$9.3M
Role of RhCMV in shaping the SIV proviral landscapeR01AI167644 · NIAID · TULANE UNIVERSITY OF LOUISIANA · 2023 to 2025
$2.6M
Mathematical modeling of optimal therapeutic combinations for HIV cureR01AI150500 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Joshua Tisdell Schiffer · 2022 to 2024
$1.0M
Phylodynamic mechanisms of HIV reservoir seeding and maintenanceR01AI186721 · FRED HUTCHINSON CANCER CENTER · 2025 to 2025
$861k
Early intervention with anti-proliferative therapy close to ART initiation to limit long-term SIV persistenceR01AI179457 · FRED HUTCHINSON CANCER CENTER · 2025 to 2025
$846k
Deep sequencing of the HIV latent reservoir to discern mechanisms of clonal proliferation and HIV persistenceR21AI186783 · JOHNS HOPKINS UNIVERSITY · 2025 to 2025
$213k
NIAID NIH HHS K25 AI155224NIAID NIH HHS R01 AI150500NIAID NIH HHS R01 AI167644NIAID NIH HHS R01 AI179457NIAID NIH HHS R01 AI186721NIAID NIH HHS R21 AI186783NIH HHS P51 OD011104The Foundation for AIDS Research 11066-76-RPRL
6 · The paper itself

Abstract

Antiretroviral therapy (ART) suppresses HIV replication in people living with HIV (PWH), but a persistent population of reservoir cells prevents cure. Reservoir cells are mostly anatomically dispersed, latently infected CD4+ T cells harboring one copy of chromosomally integrated, replication-competent HIV proviral DNA. Despite their low frequency (0.01%-0.1%) among CD4+ T cells and the quiescence of most genetically intact proviruses, viremia usually recurs within weeks after ART cessation. When PWH are not on ART, the reservoir is sustained through viral infection and infected cell proliferation. During suppressive ART, HIV reservoir cells persist via mechanisms sustaining uninfected CD4+ T cells including antigen-responsive and homeostatic clonal proliferation, programmed cell death, and T cell subset differentiation. Rates of latently infected cell proliferation and death must exist in quasi-equilibrium to explain limited change in reservoir volume over decades of ART, and the rarity of cancers or lymphoproliferative disorders emerging from infected cells. Some reservoir cells are under additional selection forces during ART, illustrated by slightly higher clearance rates of genetically intact versus replication-defective HIV proviral DNA and by a gradual transition to a less transcriptionally active and more clonal reservoir. While a small but meaningful percentage of latently infected cells are negatively selected due to lytic viral replication or elimination by adaptive immune responses, most reservoir cell death occurs independently of harboring intact HIV DNA. Given that HIV is often a passenger in reservoir cells, CD4+ T cell proliferation, targeted death, and subset differentiation may be viable therapeutic targets for curative interventions.

Indexed as

CD4-Positive T-LymphocytesHIV-1HIV InfectionsVirus LatencyAnti-HIV AgentsHumansProvirusesViral LoadVirus ReplicationAnti-HIV Agentshuman immunodeficiency virusmathematical modeling

Identifiers

PMID40464563
PMCPMC12282085

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.